OtherClinical Investigations (Human)
First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
Neeta Pandit-Taskar, Michael Postow, Matthew Hellmann, James Harding, Christopher Barker, Joseph O'Donoghue, Martha Ziolkowska, Shutian Ruan, Serge Lyashchenko, Frank Tsai, Michael Farwell, Tara Mitchell, Ron Korn, William Le, Jason Lewis, Wolfgang Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna Wu and Jedd Wolchok
Journal of Nuclear Medicine October 2019, jnumed.119.229781; DOI: https://doi.org/10.2967/jnumed.119.229781
Neeta Pandit-Taskar
1 Memorial Sloan Kettering Cancer Center, United States;
Michael Postow
1 Memorial Sloan Kettering Cancer Center, United States;
Matthew Hellmann
1 Memorial Sloan Kettering Cancer Center, United States;
James Harding
1 Memorial Sloan Kettering Cancer Center, United States;
Christopher Barker
1 Memorial Sloan Kettering Cancer Center, United States;
Joseph O'Donoghue
1 Memorial Sloan Kettering Cancer Center, United States;
Martha Ziolkowska
1 Memorial Sloan Kettering Cancer Center, United States;
Shutian Ruan
1 Memorial Sloan Kettering Cancer Center, United States;
Serge Lyashchenko
1 Memorial Sloan Kettering Cancer Center, United States;
Frank Tsai
2 Honor Health;
Michael Farwell
3 University of Pennsylvania;
Tara Mitchell
3 University of Pennsylvania;
Ron Korn
4 Imaging Endpoints;
William Le
5 ImaginAb, Inc.
Jason Lewis
1 Memorial Sloan Kettering Cancer Center, United States;
Wolfgang Weber
1 Memorial Sloan Kettering Cancer Center, United States;
Deepak Behera
5 ImaginAb, Inc.
Ian Wilson
5 ImaginAb, Inc.
Michael Gordon
2 Honor Health;
Anna Wu
5 ImaginAb, Inc.
Jedd Wolchok
1 Memorial Sloan Kettering Cancer Center, United States;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
Neeta Pandit-Taskar, Michael Postow, Matthew Hellmann, James Harding, Christopher Barker, Joseph O'Donoghue, Martha Ziolkowska, Shutian Ruan, Serge Lyashchenko, Frank Tsai, Michael Farwell, Tara Mitchell, Ron Korn, William Le, Jason Lewis, Wolfgang Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna Wu, Jedd Wolchok
Journal of Nuclear Medicine Oct 2019, jnumed.119.229781; DOI: 10.2967/jnumed.119.229781
First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
Neeta Pandit-Taskar, Michael Postow, Matthew Hellmann, James Harding, Christopher Barker, Joseph O'Donoghue, Martha Ziolkowska, Shutian Ruan, Serge Lyashchenko, Frank Tsai, Michael Farwell, Tara Mitchell, Ron Korn, William Le, Jason Lewis, Wolfgang Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna Wu, Jedd Wolchok
Journal of Nuclear Medicine Oct 2019, jnumed.119.229781; DOI: 10.2967/jnumed.119.229781
Jump to section
Related Articles
Cited By...
- Impact of human CD8+ T cell senescence on 89Zr radiolabelling and homing properties
- First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody
- Development of 89Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration
- Single-Domain Antibody Theranostics on the Horizon
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
- Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
- Molecular imaging to support cancer immunotherapy
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
- Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
- Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies
- Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
- Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy
- Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
- Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial
- ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Quo Vadis, Molecular Imaging?
- Can Molecular Imaging Measure T-cell Activation?
- The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment